MedTrace Logo

Longitudinal Protocol for Granulomatosis With Polyangiitis (Wegener's) and Microscopic Polyangiitis

NCT00315393 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1046

Last updated 2022-07-12

No results posted yet for this study

Summary

Granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA) are two rare immune system disorders that cause the inflammation of blood vessels, or vasculitis. In order to properly treat these diseases, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of disease in people with GPA or MPA.

Conditions

  • Granulomatosis With Polyangiitis
  • Microscopic Polyangiitis
  • Wegener's

Sponsors & Collaborators

  • Office of Rare Diseases (ORD)

    collaborator NIH

  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

    collaborator NIH

  • Rare Diseases Clinical Research Network

    collaborator NETWORK

  • University of Pennsylvania

    lead OTHER

Principal Investigators

  • Peter A. Merkel, MD, MPH · University of Pennsylvania

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00315393 on ClinicalTrials.gov